Navigation Links
Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition

Rochester, NY (PRWEB) January 15, 2014

The Microcompetition with Foreign DNA theory explains how latent viruses can cause a major disease. One of these latent viruses is the Epstein Barr Virus (EBV), and one of these diseases is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys the body’s joints. As predicted by the theory, a study found that RA patients have high concentrations of EBV DNA in their bodies (1).

What is Microcompetition?

Dr. Hanan Polansky discovered that foreign DNA fragments, called N-boxes, cause most major diseases. When the foreign N-boxes belong to a virus, Microcompetition between the viral DNA and the human DNA can lead to disease. As predicted by Dr. Hanan Polansky, many studies found fragments of DNA that belong to these viruses in many diseased tissues, such as tumors, clogged arteries (arterial plaque), and specifically arthritic joints.

Dr. Hanan Polansky's discovery has important implications. It suggests that medicines can cure and even prevent major diseases, such as rheumatoid arthritis, by targeting the foreign DNA fragments in the human body.

As predicted by the Microcompetition theory, the study on EBV and RA showed that patients with rheumatoid arthritis have high numbers of EBV. “Research has revealed increased viral load, high titers of EBV-directed antibodies, and decreased cell-mediated
control of EBV in RA patients compared to healthy controls (1).”

What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys the body’s joints. The disease “causes premature mortality, disability and compromised quality of life (3).” In addition, study authors wrote that RA “prevalence in women is twofold to fourfold that in men. RA has enormous personal, social, and economic impact; women with RA have overall mortality rates 2.3-fold those in age-matched controls… (2).”

The currently accepted view by the medical community says that there is no known cure for RA.

The CBCD believes that the medical community should learn more about Microcompetition. In addition, the CBCD believes that interrupting the process of Microcompetition, as described by Dr. Hanan Polansky in his ground-breaking book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease,” should be the basis for new therapies targeting RA.

To learn more about Dr. Hanan Polansky’s research and the Theory of Microcompetition with Foreign DNA, visit:


(1) Epstein-Barr Virus in Systemic Autoimmune Diseases. Published on August 24, 2013.

(2) Epstein–Barr virus and rheumatoid arthritis: is there a link? Published on January 16, 2013

(3) CDC - Rheumatoid Arthritis. Last Updated on November 19, 2012.

(4) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. Nature Materials study: Graphene invisible to water
3. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
4. Nature Materials study: Boosting heat transfer with nanoglue
5. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
6. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
9. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
10. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
11. Study: Higher Hepatitis C Infection During Acupuncture in Asian Americans; polyDNA Recommends That Doctors Prescribe Gene-Eden-VIR against HCV
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):